| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2138417 | Leukemia Research | 2009 | 4 Pages |
Abstract
Expression of the anti-apoptotic myeloid cell leukemia-1 (MCL-1) gene is a novel prognostic factor in B-cell chronic lymphocytic leukemia (B-CLL). Vascular and endothelial growth factor (VEGF) and interleukin-6 (IL-6) are able to upregulate MCL-1 via autocrine signaling loops. In 88 B-CLL patients, we found a strong correlation of MCL-1 gene expression with VEGF (P < 10−7) but not with IL-6 mRNA levels. VEGF but not IL-6 expression influenced patient prognosis. VEGF may be a positive autocrine in vivo regulator of MCL-1 in B-CLL. Inhibition of VEGF and its signaling may prove to be useful in the treatment of B-CLL patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lauren Véronèse, Olivier Tournilhac, Pierre Verrelle, Frédéric Davi, Guillaume Dighiero, Emmanuel Chautard, Richard Veyrat-Masson, Fabrice Kwiatkowski, Carole Goumy, Laetitia Gouas, Jacques-Olivier Bay, Philippe Vago, Andrei Tchirkov,